Jiffin Benjamin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiffin Benjamin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Julien Subburayalu
TU Dresden, Center for Regenerative Therapies Dresden (CRTD), 01307 Dresden, Germany
2 shared publications - Michael H. Sieweke
Aix Marseille University, CNRS, INSERM, CIML, Marseille, France
2 shared publications - Sethuraman Subramanian
TU Dresden, Center for Regenerative Therapies Dresden (CRTD), 01307 Dresden, Germany
2 shared publications - Adam Strzelczyk
Epilepsy Center Frankfurt Rhine‐Main, Department of Neurology Goethe‐University Frankfurt Frankfurt am Main Germany
1 shared publication - Alexandra Lucaciu
Institute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany
1 shared publication Anka Swiersy
TU Dresden, Center for Regenerative Therapies Dresden (CRTD), 01307 Dresden, Germany
1 shared publication
Latest Publications
- Open Access
Stemness overcomes IFNγ-induced antitumour exhaustion in human macrophages
Macrophages hold great promise for antitumour therapies 1–4 , particularly owing to their ability to infiltrate solid tumours 5 . Yet therapeutic success has been limited 6,7 , because macrophages exhibit rapid exhaustion of antitumorigenic activity in the tumour 5,8,9 . Here, we induced a stem-like self-renewal programme in human induced pluripotent stem cell (iPSC)-derived macrophages by deleting the self-renewal restricting transcription factors MAFB and MAF (MAF-DKO). Human MAF-DKO macrophages showed activated stem cell signatures, increased clonogenicity and proliferative potential. Increased self-renewal capacity was accompanied by enhanced mitochondrial fitness and invigorated energy metabolism. Importantly, these stemness features prevented exhaustion, cellular aging-associated parameters and loss of energy efficiency that are typically associated with proinflammatory macrophage activation. In addition, activated MAF-DKO macrophages showed a broad loss of IFNγ-triggered immunosuppressive pathways 10,11 , induced a super-activated state with robust cytotoxic activity and resisted exhaustion upon tumour cell exposure. Consequently, activated MAF-DKO macrophages showed intratumoral persistence with a stable antitumoral phenotype in vivo, conferred robust reduction of tumour burden and extended survival of tumourbearing mice. Together, this demonstrates that the induction of stemness in human macrophages can overcome critical roadblocks of antitumour therapy by conferring resistance to activation-triggered exhaustion of antitumour activity in the TME.
Open AccessStemness overcomes IFNγ-induced antitumour exhaustion in human macrophages
Macrophages hold great promise for antitumour therapies 1–4 , particularly owing to their ability to infiltrate solid tumours 5 . Yet therapeutic success has been limited 6,7 , because macrophages exhibit rapid exhaustion of antitumorigenic activity in the tumour 5,8,9 . Here, we induced a stem-like self-renewal programme in human induced pluripotent stem cell (iPSC)-derived macrophages by deleting the self-renewal restricting transcription factors MAFB and MAF (MAF-DKO). Human MAF-DKO macrophages showed activated stem cell signatures, increased clonogenicity and proliferative potential. Increased self-renewal capacity was accompanied by enhanced mitochondrial fitness and invigorated energy metabolism. Importantly, these stemness features prevented exhaustion, cellular aging-associated parameters and loss of energy efficiency that are typically associated with proinflammatory macrophage activation. In addition, activated MAF-DKO macrophages showed a broad loss of IFNγ-triggered immunosuppressive pathways 10,11 , induced a super-activated state with robust cytotoxic activity and resisted exhaustion upon tumour cell exposure. Consequently, activated MAF-DKO macrophages showed intratumoral persistence with a stable antitumoral phenotype in vivo, conferred robust reduction of tumour burden and extended survival of tumourbearing mice. Together, this demonstrates that the induction of stemness in human macrophages can overcome critical roadblocks of antitumour therapy by conferring resistance to activation-triggered exhaustion of antitumour activity in the TME.
- Open Access
Stroke-induced lipocalin-2-expressing red pulp macrophages reprogram peripheral immunity
Acute ischemic stroke (AIS) induces profound systemic immune alterations that contribute to infection susceptibility. Here, we identify lipocalin-2 (LCN-2) as a rapidly induced and conserved regulator of stroke-associated immunosuppression. Using 3-MACE-Seq, cytokine profiling, and immunofluorescence in C57BL/6J mice subjected to transient middle cerebral artery occlusion (tMCAO), we show that LCN-2 is strongly upregulated in splenic red pulp macrophages (RPMs) within 24 hours and again 7 days post-tMCAO. LCN-2-expressing RPMs form immunological synapses with CD3+ T cells, thereby impacting T cell trafficking. Recombinant LCN-2 directly reprogrammed T cells and monocytes toward hyporesponsive, tolerogenic phenotypes by suppressing inflammatory cytokines, impairing chemotaxis, enhancing phagocytosis, and uncoupling oxidative burst. Human spleens likewise displayed LCN-2-expressing CD68+ RPMs, and LCN-2 preconditioning of monocytes reproduced reduced HLA-DR, CD80, CD206, and ROS with increased uptake of E. coli bioparticles. These findings identify LCN-2 signaling as a central or-chestrator of stroke-induced peripheral immunoreprogramming and a potential therapeutic target to mitigate post-stroke immunodepression.
Open AccessStroke-induced lipocalin-2-expressing red pulp macrophages reprogram peripheral immunity
Acute ischemic stroke (AIS) induces profound systemic immune alterations that contribute to infection susceptibility. Here, we identify lipocalin-2 (LCN-2) as a rapidly induced and conserved regulator of stroke-associated immunosuppression. Using 3-MACE-Seq, cytokine profiling, and immunofluorescence in C57BL/6J mice subjected to transient middle cerebral artery occlusion (tMCAO), we show that LCN-2 is strongly upregulated in splenic red pulp macrophages (RPMs) within 24 hours and again 7 days post-tMCAO. LCN-2-expressing RPMs form immunological synapses with CD3+ T cells, thereby impacting T cell trafficking. Recombinant LCN-2 directly reprogrammed T cells and monocytes toward hyporesponsive, tolerogenic phenotypes by suppressing inflammatory cytokines, impairing chemotaxis, enhancing phagocytosis, and uncoupling oxidative burst. Human spleens likewise displayed LCN-2-expressing CD68+ RPMs, and LCN-2 preconditioning of monocytes reproduced reduced HLA-DR, CD80, CD206, and ROS with increased uptake of E. coli bioparticles. These findings identify LCN-2 signaling as a central or-chestrator of stroke-induced peripheral immunoreprogramming and a potential therapeutic target to mitigate post-stroke immunodepression.